Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000343003> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2000343003 endingPage "25" @default.
- W2000343003 startingPage "18" @default.
- W2000343003 abstract "Migraineurs may continue to experience attacks, despite daily use of one or more agents from a wide range of drugs, including β ‐blockers, calcium channel blockers, serotonin antagonists, tricyclic antidepressants, monoamine oxidase inhibitors, and antiepileptic agents. Divalproex sodium is the only antiepileptic drug approved for migraine prevention. Gabapentin, topiramate, and other antiepileptic agents are being evaluated for migraine prevention and treatment. Prospective, double‐blind, placebo‐controlled clinical trials of divalproex, gabapentin, and topiramate for migraine prevention generally were composed of a prospective baseline period, a dose titration period, and a fixed‐dose treatment period. The primary efficacy variable was a reduction in the 28‐day frequency of migraine headache. Patients receiving divalproex for 12 weeks at doses up to 1500 mg/day achieved significant decreases in the migraine frequency ( P < .05), corresponding to reductions of 30% to 40% compared with baseline. Nearly half of the divalproex‐treated patients had a 50% or more reduction from baseline in headache frequencies ( P .05). Asthenia, vomiting, somnolence, tremor, and alopecia were common adverse events associated with divalproex. Significant reductions in migraine frequency were also observed with gabapentin (1800 to 2400 mg/day) when compared with placebo ( P < .01), and nearly half of all patients treated at the highest dose experienced a reduction in headache rate of 50% or more. Somnolence was the most commonly reported adverse event among the gabapentin‐treated patients. Two single‐center, double‐blind, placebo‐controlled clinical trials evaluated topiramate for migraine prevention. A lower 28‐day migraine frequency was seen during 18 weeks of administration at a maximum daily dose of 200 mg ( P = .09). In a second study, a significantly lower mean 28‐day migraine frequency was observed during 16 weeks of treatment with topiramate ( P = .0015). Mean reduction in migraine frequency was also significantly greater in topiramate‐treated patients ( P = .0037). Paresthesias, diarrhea, somnolence, and altered taste were commonly reported adverse events in the topiramate‐treated patients. Unlike some patients given divalproex or gabapentin, some given topiramate reported weight loss. Large, double‐blind, placebo‐controlled trials may prove the effectiveness of novel antiepileptic drugs in migraine prevention." @default.
- W2000343003 created "2016-06-24" @default.
- W2000343003 creator A5064198109 @default.
- W2000343003 date "2001-11-01" @default.
- W2000343003 modified "2023-09-27" @default.
- W2000343003 title "Antiepileptic Drugs in Migraine Prevention" @default.
- W2000343003 cites W1842552614 @default.
- W2000343003 cites W1963569078 @default.
- W2000343003 cites W1964060547 @default.
- W2000343003 cites W1970386351 @default.
- W2000343003 cites W2013640699 @default.
- W2000343003 cites W2017549423 @default.
- W2000343003 cites W2087030391 @default.
- W2000343003 cites W2089821139 @default.
- W2000343003 cites W2123978981 @default.
- W2000343003 cites W4245946884 @default.
- W2000343003 doi "https://doi.org/10.1046/j.1526-4610.2001.01154-4.x" @default.
- W2000343003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11903536" @default.
- W2000343003 hasPublicationYear "2001" @default.
- W2000343003 type Work @default.
- W2000343003 sameAs 2000343003 @default.
- W2000343003 citedByCount "46" @default.
- W2000343003 countsByYear W20003430032012 @default.
- W2000343003 countsByYear W20003430032013 @default.
- W2000343003 countsByYear W20003430032015 @default.
- W2000343003 countsByYear W20003430032017 @default.
- W2000343003 countsByYear W20003430032018 @default.
- W2000343003 countsByYear W20003430032019 @default.
- W2000343003 countsByYear W20003430032023 @default.
- W2000343003 crossrefType "journal-article" @default.
- W2000343003 hasAuthorship W2000343003A5064198109 @default.
- W2000343003 hasConcept C118552586 @default.
- W2000343003 hasConcept C126322002 @default.
- W2000343003 hasConcept C142724271 @default.
- W2000343003 hasConcept C197934379 @default.
- W2000343003 hasConcept C204787440 @default.
- W2000343003 hasConcept C27081682 @default.
- W2000343003 hasConcept C2775858608 @default.
- W2000343003 hasConcept C2776174506 @default.
- W2000343003 hasConcept C2776608144 @default.
- W2000343003 hasConcept C2776809841 @default.
- W2000343003 hasConcept C2777683783 @default.
- W2000343003 hasConcept C2778186239 @default.
- W2000343003 hasConcept C2778541603 @default.
- W2000343003 hasConcept C2778541695 @default.
- W2000343003 hasConcept C2779034229 @default.
- W2000343003 hasConcept C2780564907 @default.
- W2000343003 hasConcept C2908949014 @default.
- W2000343003 hasConcept C42219234 @default.
- W2000343003 hasConcept C71924100 @default.
- W2000343003 hasConceptScore W2000343003C118552586 @default.
- W2000343003 hasConceptScore W2000343003C126322002 @default.
- W2000343003 hasConceptScore W2000343003C142724271 @default.
- W2000343003 hasConceptScore W2000343003C197934379 @default.
- W2000343003 hasConceptScore W2000343003C204787440 @default.
- W2000343003 hasConceptScore W2000343003C27081682 @default.
- W2000343003 hasConceptScore W2000343003C2775858608 @default.
- W2000343003 hasConceptScore W2000343003C2776174506 @default.
- W2000343003 hasConceptScore W2000343003C2776608144 @default.
- W2000343003 hasConceptScore W2000343003C2776809841 @default.
- W2000343003 hasConceptScore W2000343003C2777683783 @default.
- W2000343003 hasConceptScore W2000343003C2778186239 @default.
- W2000343003 hasConceptScore W2000343003C2778541603 @default.
- W2000343003 hasConceptScore W2000343003C2778541695 @default.
- W2000343003 hasConceptScore W2000343003C2779034229 @default.
- W2000343003 hasConceptScore W2000343003C2780564907 @default.
- W2000343003 hasConceptScore W2000343003C2908949014 @default.
- W2000343003 hasConceptScore W2000343003C42219234 @default.
- W2000343003 hasConceptScore W2000343003C71924100 @default.
- W2000343003 hasIssue "s1" @default.
- W2000343003 hasLocation W20003430031 @default.
- W2000343003 hasLocation W20003430032 @default.
- W2000343003 hasOpenAccess W2000343003 @default.
- W2000343003 hasPrimaryLocation W20003430031 @default.
- W2000343003 hasRelatedWork W1584902003 @default.
- W2000343003 hasRelatedWork W1984761434 @default.
- W2000343003 hasRelatedWork W2000343003 @default.
- W2000343003 hasRelatedWork W2031080648 @default.
- W2000343003 hasRelatedWork W2033668930 @default.
- W2000343003 hasRelatedWork W2037133700 @default.
- W2000343003 hasRelatedWork W2152694928 @default.
- W2000343003 hasRelatedWork W2384356687 @default.
- W2000343003 hasRelatedWork W2415541289 @default.
- W2000343003 hasRelatedWork W54331016 @default.
- W2000343003 hasVolume "41" @default.
- W2000343003 isParatext "false" @default.
- W2000343003 isRetracted "false" @default.
- W2000343003 magId "2000343003" @default.
- W2000343003 workType "article" @default.